Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026

Phase 3amlenetugPositive

AI Analysis

Summary

Lundbeck will present Phase III MASCOT data on amlenetug for multiple system atrophy at MDS 2026 conference, including clinical profile characterization and participant diversity findings from their ongoing global trial.

Clinical Trial Data

Phase

Phase III

Outcome Details

Late-breaking Phase III MASCOT oral presentation characterizing clinical profile and participant diversity

Importance:6/10

Sentiment:

0.30

movement disordersmultiple system atrophyParkinson's diseasePhase IIIclinical trialMDS 2026 conference

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Pharma on October 2, 2026 6:31 AM

Read Original